Cargando…
Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4
Given the poor track record to date of animal models for creating cardioprotective drugs, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have been proposed as a therapeutically relevant human platform to guide target validation and cardiac drug development. Mitogen-Activated Protein K...
Autores principales: | Golforoush, Pelin A., Narasimhan, Priyanka, Chaves-Guerrero, Patricia P., Lawrence, Elsa, Newton, Gary, Yan, Robert, Harding, Sian E., Perrior, Trevor, Chapman, Kathryn L., Schneider, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374628/ https://www.ncbi.nlm.nih.gov/pubmed/32694738 http://dx.doi.org/10.1038/s41598-020-68907-1 |
Ejemplares similares
-
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo
por: Fiedler, Lorna R., et al.
Publicado: (2020) -
MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo
por: Fiedler, Lorna R., et al.
Publicado: (2019) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes
por: Knowles, David A, et al.
Publicado: (2018)